AstraZeneca says lung cancer therapy outperformed with chemotherapy
jetcityimage/iStock Editorial via Getty Images
AstraZeneca (NASDAQ:AZN) announced Monday that lung cancer patients who received its tyrosine kinase inhibitor Tagrisso in combination with chemotherapy lived longer without cancer worsening.
Results were from the company's FLAURA2 Phase 3 trial, which enrolled patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Tagrisso is indicated in the U.S. as a first-line therapy for EGFRm NSCLC.
The Anglo-Swedish drugmaker noted that patients on Tagrisso plus chemotherapy showed a median progression-free survival of 25.5 months in FLAURA2 compared to 16.7 months in those who received Tagrisso monotherapy.
The improvement of 8.8 months based on investigator assessment was statistically significant and clinically meaningful, AstraZeneca (AZN) said, adding that PFS results from blinded independent central review (BICR) also showed a median PFS improvement of 9.5 months.
The global trial involved 557 patients with locally advanced or metastatic EGFRm NSCLC who received the once-daily oral treatment with or without chemotherapy in over 150 study sites across more than 20 countries.
At the time of the analysis, there was a favorable trend in overall survival (OS), the golden standard used to measure the efficacy of a cancer drug. However, the data was immature at the time, AstraZeneca (AZN) said, adding that FLAURA2 continues with a view to assess the secondary endpoint of OS.
In terms of safety, the incidence of Grade 3 or higher AEs stood at 64% and 27% in the Tagrisso plus chemotherapy arm and the Tagrisso monotherapy arm, respectively.

More on AstraZeneca

Seeking Alphaâs Quant Rating on AstraZeneca
Historical earnings data for AstraZeneca
Dividend scorecard for AstraZeneca
Financial information for AstraZeneca
AstraZeneca: Robust Performance And Promising Growth Initiatives
AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)
AstraZeneca: Solid Earnings Report Reinforces Medium To Long-Term Upside

AstraZeneca PLC (AZN) Q2 2023 Earnings Call Transcript
AstraZeneca Ultomiris label expansion declined in U.S.
AstraZeneca, Daiichi win two FDA breakthrough tags for Enhertu
AstraZeneca latest drugmaker to challenge Medicare drug price negotiation
AstraZeneca sued in London over adverse events linked to COVID shot